Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Five-year change in brain metabolism across the spectrum of cognitive impairment in older adults: a quantitative MRI study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Jiani, Oishi Kumiko, Soldan Anja, Pettigrew Corinne, Lin Zixuan, Zhu Yuxin, Jiang Dengrong, Li Xin, Gou Yifan, Moghekar Abhay, Liu Peiying, Bakker Arnold, Oishi Kenichi, Albert Marilyn, Lu Hanzhang
Аннотация
INTRODUCTION: It is desirable to measure brain metabolism without needing ionizing radiation and elucidate its time trajectory. This study employed a positron emission tomography -validated, non-invasive magnetic resonance imaging (MRI) technique to characterize longitudinal changes in cerebral metabolic rate of oxygen (CMRO2) in both cognitively normal and impaired older adults.
METHODS: Participants received serial MRI-based CMRO2 scans between 2015 and 2025. Levels of AD pathology were measured in cerebrospinal fluid and plasma at the initial MRI.
RESULTS: At the initial visit, participants with MCI/dementia had lower CMRO2 than normal participants. In the longitudinal analyses, CMRO2 decreased over time in those who were cognitively impaired but remained unchanged in normals. Among normal participants, higher initial levels of total tau and phosphorylated tau at threonine 181 were associated with an increase in CMRO2 during follow-up, especially in amyloid-positive individuals.
DISCUSSION: Aside from the well-known metabolic slowdown in the later phases of AD, the brain exhibits tau-dependent hypermetabolism during the preclinical stage.
METHODS: Participants received serial MRI-based CMRO2 scans between 2015 and 2025. Levels of AD pathology were measured in cerebrospinal fluid and plasma at the initial MRI.
RESULTS: At the initial visit, participants with MCI/dementia had lower CMRO2 than normal participants. In the longitudinal analyses, CMRO2 decreased over time in those who were cognitively impaired but remained unchanged in normals. Among normal participants, higher initial levels of total tau and phosphorylated tau at threonine 181 were associated with an increase in CMRO2 during follow-up, especially in amyloid-positive individuals.
DISCUSSION: Aside from the well-known metabolic slowdown in the later phases of AD, the brain exhibits tau-dependent hypermetabolism during the preclinical stage.